Background

C-C motif chemokine receptor 5 (CCR5) has long been a key target in research aimed at blocking the infection pathway of Human Immunodeficiency Virus type 1 (HIV-1). As it is known that reducing the expression of this protein, which acts as a co-receptor for viral entry on the cell surface, can induce infection resistance, focus has been placed on gene editing and transcriptional regulation technologies. The academic community has also paid attention to mechanisms that regulate protein translation efficiency at the transcript level, not just at the transcriptional stage.

In particular, programmed ribosomal frameshifting (PRF), in which the reading frame shifts during the translation of messenger RNA (mRNA), has been identified as a sophisticated mechanism for regulating gene expression not only in viruses but also in eukaryotic cells. A study published in Nature in 2020 proposed a hypothesis that microRNA (miRNA) and Nonsense-Mediated mRNA Decay (NMD) pathways combine to control CCR5 translation. The explanation was that while frameshifting occurs rarely under normal conditions, the binding of specific miRNAs causes ribosome stalling, creating premature termination codons, which ultimately leads to the degradation of the transcript via the NMD pathway.

The model of inhibiting cell surface receptor expression through non-coding RNA and ribosome translocation control attracted significant attention. This was because it appeared feasible to develop therapeutic strategies that lower CCR5 levels using RNA-binding oligonucleotides or small-molecule compounds, without the need for complex gene-editing tools. However, immediately after the announcement, questions arose during independent reproducibility verification. The results showing that -1 frameshifting in mammalian genes occurs at a significant frequency to decisively inhibit protein expression were not consistently reproduced in other researchers' ribosome profiling and mass spectrometry studies.

Key Findings

The formal retraction notice published in Nature this time officially confirmed that significant errors and integrity flaws exist throughout the core data of the study. Following the review of replication experiments and raw data, the authors and journal editors admitted that the dual luciferase reporter measurements, which reported a frameshifting efficiency of over 10% on CCR5 mRNA, contained confounding factors.

The most decisive problem revealed during the investigation was the Western blot quantification data for the experiment inducing frameshifting following miRNA binding. The conclusion that UPF1, an NMD-related protein, aggregates upon binding of specific miR-1224, thereby promoting transcript collapse, lost statistical significance during the re-validation stage. Traces of inappropriate image manipulation were identified during the process of adjusting protein band intensities between the control and experimental groups, and discrepancies existed between the original gel images and the data presented in the paper.

Independent analyses based on single-molecule fluorescence resonance energy transfer (smFRET) conducted by other research groups also showed that the frequency at which CCR5 mRNA-specific hairpin structures induce ribosomal stalling was significantly lower than the values claimed in the original paper. The probability of ribosomes shifting the reading frame was less than 0.5% under natural conditions. It was not at a level that could lead to the suppression of intracellular CCR5 expression. Ultimately, the authors deemed it difficult to ensure the reliability of the quantitative data supporting their core argument and agreed to withdraw the paper.

Implications and Outlook

This paper retraction demonstrates why a strict orthogonal verification system is essential in the process of identifying post-transcriptional regulation mechanisms. The link between ribosomal frameshifting and the NMD pathway was a biologically attractive hypothesis, but results relying on minute fluorescent signals or manipulated electrophoresis bands failed to withstand scientific scrutiny. A consensus has formed that future eukaryotic PRF research must move beyond artificial reporter systems and adopt high-resolution mass spectrometry (Ribo-MS), which directly captures endogenous peptides within cells, as a mandatory standard.

From the perspective of a drug development pipeline, there is an aspect of having mitigated development risks early on. Research teams designing miRNA analogs or frameshift-inducing agents based on flawed mechanisms can now reduce unnecessary preclinical costs. Conversely, the search for alternative pathways aiming to suppress CCR5 expression is expected to revert to gene editing technologies (CRISPR-Cas9) or existing monoclonal antibody blockers.

At the same time, integrity verification protocols within the academic community are becoming increasingly stringent. Major journals, including Nature, are mandating the submission of raw, unprocessed gel images along with raw count sequencing files when submitting RNA structure analysis and translation quantification data. The verification system of the Open Science community, which independently monitors data reproducibility, has established itself as a powerful pillar supplementing the blind spots of journal peer review.